4//SEC Filing
Dawson Michael John 4
Accession 0001209191-21-029066
CIK 0001357459other
Filed
Apr 28, 8:00 PM ET
Accepted
Apr 29, 5:46 PM ET
Size
16.0 KB
Accession
0001209191-21-029066
Insider Transaction Report
Form 4
Dawson Michael John
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-04-27+5,438→ 5,438 totalExercise: $27.59Exp: 2027-02-10→ Common Stock (5,438 underlying) - Award
Stock Option (Right to Buy)
2021-04-27+5,084→ 5,084 totalExercise: $41.20Exp: 2029-03-22→ Common Stock (5,084 underlying) - Award
Stock Option (Right to Buy)
2021-04-27+1,962→ 1,962 totalExercise: $41.20Exp: 2029-03-22→ Common Stock (1,962 underlying) - Award
Stock Option (Right to Buy)
2021-04-27+2,800→ 2,800 totalExercise: $26.85Exp: 2030-02-19→ Common Stock (2,800 underlying) - Award
Stock Option (Right to Buy)
2021-04-27+20,391→ 20,391 totalExercise: $53.33Exp: 2028-07-24→ Common Stock (20,391 underlying)
Footnotes (8)
- [F1]The stock option vested in four equal quarterly installments from the vesting commencement date.
- [F2]Received in exchange for a stock option to acquire 200,000 shares of common stock of Leading BioSciences, Inc. ("LBS") for $0.75 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc.
- [F3]The stock option vests according to the following schedule: 17% of the shares underlying the option vests on grant date and the remaining 83% vests in 10 quarterly installments thereafter beginning on September 30, 2018.
- [F4]Received in the Merger in exchange for a stock option to acquire 750,000 shares of LBS common stock for $1.45 per share.
- [F5]The stock option vests according to the following schedule: 33% of the shares underlying the option vests on grant date and the remaining 67% vests in eight equal quarterly installments thereafter beginning on March 31, 2019.
- [F6]Received in the Merger in exchange for a stock option to acquire 187,000 shares of LBS common stock for $1.12 per share.
- [F7]Received in the Merger in exchange for a stock option to acquire 72,200 shares of LBS common stock for $1.12 per share.
- [F8]Received in the Merger in exchange for a stock option to acquire 103,000 shares of LBS common stock for $0.73 per share.
Documents
Issuer
PALISADE BIO, INC.
CIK 0001357459
Entity typeother
Related Parties
1- filerCIK 0001849790
Filing Metadata
- Form type
- 4
- Filed
- Apr 28, 8:00 PM ET
- Accepted
- Apr 29, 5:46 PM ET
- Size
- 16.0 KB